A. Babouri

发表

Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn's Disease

B. Flourié, L. Siproudhis, L. Peyrin-Biroulet, 2015, Inflammatory bowel diseases.

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

L. Peyrin-Biroulet, A. Oussalah, M. Bensenane, 2009, Alimentary pharmacology & therapeutics.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer

F. Carrat, H. Sokol, L. Peyrin-Biroulet, 2013, Gut.

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

V. de Lédinghen, T. Asselah, D. Thabut, 2021, BMC Infectious Diseases.

Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.

L. Peyrin-Biroulet, X. Hébuterne, J. Filippi, 2014, Journal of Crohn's & colitis.

Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.

L. Peyrin-Biroulet, M. Bigard, A. Buisson, 2013, Journal of Crohn's & colitis.

Long‐term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single‐centre experience

L. Peyrin-Biroulet, A. Oussalah, X. Roblin, 2008, Alimentary pharmacology & therapeutics.

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

V. de Lédinghen, J. Zucman‐Rossi, M. Ronot, 2021, JHEP reports : innovation in hepatology.

Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn's Disease

B. Flourié, L. Siproudhis, L. Peyrin-Biroulet, 2015, Inflammatory bowel diseases.

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

L. Peyrin-Biroulet, A. Oussalah, M. Bensenane, 2009, Alimentary pharmacology & therapeutics.